Market Research Reports, Inc. has announced the addition of “EpiCast Report: Irritable Bowel Syndrome - Epidemiology Forecast to 2023” research report to their offering.
Lewes, DE -- (SBWIRE) -- 11/03/2014 -- Irritable bowel syndrome (IBS) is a chronic, relapsing gastrointestinal disorder that is characterized by abdominal discomfort or pain, bloating, and changes in bowel habit. Due to the lack of a demonstrable structural abnormality to explain these symptoms, IBS is classified as a functional gastrointestinal disorder.
This report provides an overview of the risk factors, comorbidities, and global trends for IBS in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases of IBS (diagnosed and undiagnosed) segmented by age (10–18 years, 19–34 years, 35–44 years, 45–54 years, 55–64 years, 65–74 years, 75–84 years, and ?85 years), sex, and subclassification of predominant bowel habits (diarrhea-predominant IBS [IBS-D], constipation-predominant IBS [IBS-C], mixed presentation IBS [IBS-M], and unsubtyped IBS [IBS-U]) in these markets. For this analysis, Publisher epidemiologists defined IBS using the International Classification of Diseases, Tenth Revision (ICD-10) code for IBS (K58). Additionally, to construct the epidemiological forecast for the total prevalent cases of IBS in the 7MM, Publisher epidemiologists used country-specific studies that provided the total prevalence of IBS using the Rome II diagnostic criteria.The total prevalent cases of IBS includes men and women who may or may not have been formally diagnosed as having IBS, but have been identified as having IBS symptoms using the Rome II IBS diagnostic criteria (Thompson et al., 1999).
In 2013, there were 40,777,607 total prevalent cases of IBS in the 7MM. Publisher epidemiologists forecast that the total prevalent cases in the 7MM will increase to 42,366,389 by 2023, at an Annual Growth Rate (AGR) of 0.39%. All markets, except for Germany and Japan,will see a small increase in the number of cases at varying AGRs. Since Publisher epidemiologists held the prevalence constant throughout the forecast period, the differences observed in growth are driven by changes in the underlying population dynamics of each market.
Spanning over 49 pages, “EpiCast Report: Irritable Bowel Syndrome - Epidemiology Forecast to 2023” report covering the Introduction, Epidemiology, Appendix.
Know more about this report at – http://www.marketresearchreports.com/globaldata/epicast-report-irritable-bowel-syndrome-epidemiology-forecast-2023
Find all Diseases Report at: http://www.marketresearchreports.com/diseases
About Market Research Reports, Inc.
Market Research Reports, Inc. is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.
For regular industry updates subscribe to our newsletter at: